Zeleris now licenced to treat Mycoplasma bovis - Veterinary Practice
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now


Zeleris now licenced to treat Mycoplasma bovis

Ceva Animal Health has extended the licence for Zeleris which is now indicated for the treatment of Mycoplasma bovis, one of the major pathogens responsible for bovine respiratory disease

The new licence extension means that Zeleris is licenced for the treatment of bovine respiratory disease (BRD) associated with pyrexia due to Mannheimia haemolytica, Pasteurella multocida, Histophilus somni AND Mycoplasma bovis. 

Mycoplasma bovis causes several diseases in cattle including respiratory disease in calves and arthritis, mastitis and pneumonia in older animals, generally in association with other pathogens.

Zeleris is an antibiotic and NSAID, and features the unique combination of florfenicol and meloxicam in one convenient injection.

It is ideally suited for the treatment of BRD in cattle from four weeks of age and features the NSAID of vet choice for BRD, meloxicam (according to 80 ten minute online interviews with vets that spend 50 percent of their professional time treating cattle).

Meloxicam has a duration of action of up to three days and provides anti-inflammatory, antipyretic, anti-exudative and analgesic effects, optimising long term productivity of the animal and supporting good welfare (Zeleris 400mg/ml solution for injection for cattle SPC). 

Florfenicol has a wide spectrum of activity against the major BRD bacteria, including Mycoplasma bovis, Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.  

Florfenicol has a fast and sustained duration of action from three to seven days with good distribution into the lung tissue.

It has good efficiency compared to oxytets without the need to retreat. Moreover, florfenicol is not used in human health medicine and has minimal reported resistance.

The dose rate of Zeleris of 1ml/10kg subcutaneous injection is easy for farmers (and vets) to remember and calculate, while the syringeability of Zeleris is proven to be four times faster than similar treatments, even on cold days.

Zeleris is supplied in a CLAS shock-resistant vial making it well suited for farm conditions.

Harry Walby, ruminant veterinary advisor for Zeleris at Ceva Animal Health, comments: “Mycoplasma bovis is notoriously difficult to contain and is very rarely isolated alone; it is frequently found alongside other pathogens including Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.  

“In the absence of an effective commercial vaccine, antimicrobial therapy remains the main control measure and early administration of a NSAID/antibiotic combination treatment, such as Zeleris, can aid treatment response and reduce the fever that typically comes with BRD compared with using an antibiotic treatment alone.”

For further information on Zeleris, please contact your Ceva Animal Health territory manager.

Have you heard about our
IVP Membership?

A wide range of veterinary CPD and resources by leading veterinary professionals.

Stress-free CPD tracking and certification, you’ll wonder how you coped without it.

Discover more